SCHEMBL30962749

SCHEMBL30962749

COc1nc(Nc2ccc(O[C@@H]3CCN(C(=O)OC(C)(C)C)C3)c(C)c2)ncc1C(=O)Nc1c(Cl)cccc1Br

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 6/20 0.43
▸ IGF1R P08069 2/20 0.41
▸ PIK3CA P42336 3/20 0.40
▸ PIK3CB P42338 2/20 0.40
▸ PIK3CG P48736 2/20 0.40
▸ SRC P12931 2/20 0.40
▸ EGFR P00533 3/20 0.40
▸ CCNK O75909 1/20 0.38
▸ CCNA2 P20248 1/20 0.38
▸ CDK2 P24941 1/20 0.38
▸ CCND3 P30281 1/20 0.38
▸ CDK9 P50750 1/20 0.38
▸ CDK6 Q00534 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ GPR35 Q9HC97 1/20 0.38
▸ GPR55 Q9Y2T6 1/20 0.38
▸ ERBB2 P04626 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30962655 0.96 EGFR (0.42) IGF1RSRCEGFRCCNKCCNA2
SCHEMBL30962835 0.94 JAK3 (0.41) PIK3CDIGF1RSRCEGFRCCNK
SCHEMBL30962666 0.90 JAK3 (0.42) IGF1RSRCEGFRCCNKCCNA2
SCHEMBL30962748 0.90 SRC (0.44) SRCEGFRERBB2TTK
SCHEMBL30962895 0.90 SRC (0.44) SRCEGFRERBB2TTK
SCHEMBL30962660 0.89 IGF1R (0.44) IGF1RSRCCCNKCCNA2CDK2
SCHEMBL30962735 0.89 IGF1R (0.44) IGF1RSRCCCNKCCNA2CDK2
SCHEMBL30962866 0.89 IGF1R (0.44) IGF1RSRCCCNKCCNA2CDK2
SCHEMBL30962930 0.89 SRC (0.46) SRCEGFRERBB2TTK
SCHEMBL30962929 0.89 SRC (0.46) SRCEGFRERBB2TTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4642767-A1 PYRIMIDINE CARBOXAMIDE COMPOUNDS Acrivon Therapeutics, Inc. (US) 2025-11-05 — — EP disclosed
Send feedback